We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

177 hedge funds and large institutions have $944M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

26% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 53

8% more funds holding

Funds holding: 164177 (+13)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $972M → $944M (-$28.6M)

80% less call options, than puts

Call options by funds: $85K | Put options by funds: $434K

Holders
177
Holders Change
+13
Holders Change %
+7.93%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
27
Increased
67
Reduced
53
Closed
14
Calls
$85K
Puts
$434K
Net Calls
-$349K
Net Calls Change
-$898K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$94.3M +$277K +18,010 +0.3%
AC
2
Armistice Capital
New York
$92.8M +$10.8M +700,000 +13%
RG
3
Redmile Group
California
$83.3M +$7.62M +495,103 +10%
DM
4
Deerfield Management
New York
$80.7M -$10.2M -660,754 -11%
Vanguard Group
5
Vanguard Group
Pennsylvania
$71.8M +$2.52M +163,408 +4%
State Street
6
State Street
Massachusetts
$48.7M +$9.67M +627,993 +25%
Goldman Sachs
7
Goldman Sachs
New York
$30.9M -$5.3M -344,634 -15%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$25.3M +$685K +44,478 +3%
Morgan Stanley
9
Morgan Stanley
New York
$24.2M -$47.6M -3,093,040 -67%
PCH
10
Polar Capital Holdings
United Kingdom
$23.6M -$5.39M -350,000 -19%
FLSM
11
Frazier Life Sciences Management
California
$22.9M +$6.68M +434,037 +42%
N
12
Nuveen
North Carolina
$22.4M +$192K +12,483 +0.9%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$19.7M +$508K +33,009 +3%
EA
14
Emerald Advisers
Pennsylvania
$16.4M +$5.75M +373,616 +56%
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
$13M +$4.59M +298,131 +57%
JFG
16
Jefferies Financial Group
New York
$12.9M -$1.46M -95,000 -10%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$12.7M
Millennium Management
18
Millennium Management
New York
$12.5M +$2.23M +144,846 +22%
PHP
19
Parkman Healthcare Partners
Connecticut
$11.5M +$2.59M +168,205 +30%
B
20
Braidwell
Connecticut
$9.59M -$8.62M -559,847 -48%
TCM
21
Tang Capital Management
California
$9.44M +$9.23M +600,000 New
NLVP
22
New Leaf Venture Partners
New York
$9.08M
Charles Schwab
23
Charles Schwab
California
$8.36M +$249K +16,174 +3%
Renaissance Technologies
24
Renaissance Technologies
New York
$8.34M +$1.43M +92,900 +21%
Northern Trust
25
Northern Trust
Illinois
$8.12M -$147K -9,548 -2%

DCPH Hedge Fund Activity: Q1 2024 in Review

177 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2024, worth a combined $944M — down 2.9% from $972M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new DCPH positions and 14 closed out — a net gain of 13 holders — while 67 added to existing stakes and 53 trimmed.

The largest buyer was Armistice Capital, adding an estimated $10.8M. The largest seller was Morgan Stanley, cutting an estimated $47.6M.

  • 177 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2024, up from 164 in Q4 2023.
  • Funds reported $944M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 2.9% quarter-over-quarter.
  • 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of +13 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Armistice Capital, an estimated $10.8M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Morgan Stanley, an estimated $47.6M sold.

Based on aggregated 13F filings for Q1 2024.